Monoclonal Gammopathy of Undetermined Significance (MGUS) Diagnosis and Management

Definition and Diagnostic Criteria

Monoclonal Gammopathy of Undetermined Significance (MGUS) is characterized by serum monoclonal protein < 3 g/dL, clonal bone marrow plasma cells < 10%, and absence of end-organ damage attributable to the plasma cell proliferative disorder, as defined by the International Myeloma Working Group 1, 2
The diagnostic criteria for MGUS include serum monoclonal protein < 3 g/dL, clonal bone marrow plasma cells < 10%, and absence of end-organ damage (CRAB features: hypercalcemia, renal insufficiency, anemia, and bone lesions) attributable to the plasma cell proliferative disorder 1, 2

MGUS affects approximately 3.5% of the population over 50 years of age, according to the International Myeloma Working Group 3, 4
IgG and IgA MGUS are precursor conditions of multiple myeloma, while light-chain MGUS is a precursor of light-chain multiple myeloma, and IgM MGUS is a precursor of Waldenström's macroglobulinemia and other lymphoproliferative disorders 3, 4

The average risk of progression to multiple myeloma or other lymphoproliferative disorders is approximately 1% per year, as reported by the International Myeloma Working Group 3, 4
The International Myeloma Working Group recommends risk stratification based on size of serum M protein, type of M protein, free light chain (FLC) ratio, and bone marrow plasma cell percentage 1, 2, 5

The International Myeloma Working Group recommends the following risk stratification model:

MGUS patients may experience increased risk of venous and arterial thrombosis, higher susceptibility to infections, increased risk of osteoporosis and bone fractures, and rare but serious organ damage from monoclonal protein deposition or autoantibody activity, as reported by the International Myeloma Working Group 3, 4

The International Myeloma Working Group recommends risk stratification at diagnosis to optimize follow-up and counseling, with follow-up frequency determined by risk category 1, 5
Low-risk MGUS patients should be followed every 2-3 years or at time of progression, while higher-risk MGUS patients require more frequent monitoring 5, 6
Patients with MGUS are more likely to die from conditions unrelated to their monoclonal gammopathy than from progression to malignancy, highlighting the importance of regular monitoring and counseling 5, 6